Pluri (PLUR) Gains from Sales and Divestitures (2014 - 2025)
Pluri (PLUR) reported Gains from Sales and Divestitures of $245663.0 for Q4 2025, up 1655.49% year-over-year from $13994.0 in Q4 2024, and up 39.73% quarter-over-quarter from $175811.0 in Q3 2025.
Pluri (PLUR) Gains from Sales and Divestitures (2014 - 2025) Analysis & Trends
Pluri (PLUR) has 12 years of Gains from Sales and Divestitures data on file, last reported at $245663.0 in Q4 2025.
- Gains from Sales and Divestitures for Q4 2025 came in at $245663.0, up 1655.49% year-over-year; the trailing twelve-month figure through Dec 2025 was $245663.0 (up 1655.49% YoY), and the FY2025 annual result was $307868.0, up 163.15% from the prior year.
- Gains from Sales and Divestitures climbed to $245663.0 in Q4 2025 per PLUR's latest filing, from $175811.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $504709.0 in Q2 2022 and troughed at $2657.0 in Q2 2023.
- A 5-year average of $180063.2 and a median of $179418.0 in 2023 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2021 and 2022: Gains from Sales and Divestitures slumped 100.0% in 2021, then jumped 4514.27% in 2022.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $233570.0 in 2021, then retreated by 9.11% to $212287.0 in 2022, then surged by 66.77% to $354027.0 in 2023, then tumbled by 96.05% to $13994.0 in 2024, then jumped by 1655.49% to $245663.0 in 2025.
- Business Quant data shows PLUR's Gains from Sales and Divestitures at $245663.0 in Q4 2025, $175811.0 in Q3 2025, and $307868.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Pluri | 21.85 Mn | 22.34 Mn | 86,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 245,663.00 |
| Dec 31, 2025 | 245,663.00 |
| Sep 30, 2025 | 175,811.00 |
| Sep 30, 2025 | 175,811.00 |
| Jun 30, 2025 | 307,868.00 |
| Jun 30, 2025 | 307,868.00 |
| Mar 31, 2025 | 202,884.00 |
| Mar 31, 2025 | 202,884.00 |
| Dec 31, 2024 | 13,994.00 |
| Dec 31, 2024 | 13,994.00 |
| Sep 30, 2024 | 92,677.00 |
| Sep 30, 2024 | 92,677.00 |
| Jun 30, 2024 | 116,992.00 |
| Jun 30, 2024 | 116,992.00 |
| Mar 31, 2024 | 55,121.00 |
| Mar 31, 2024 | 55,121.00 |
| Dec 31, 2023 | 354,027.00 |
| Dec 31, 2023 | 354,027.00 |
| Sep 30, 2023 | 183,025.00 |
| Sep 30, 2023 | 183,025.00 |